CytoMed Therapeutics Limited
GDTCHealthcareNASDAQBiotechnology · Last scanned Sep 4, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of Sep 3
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in. The $10.4M market capitalization puts GDTC squarely in micro-cap range for its industry. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Market Cap
$10.4M
Beta
0.05
P/E (TTM)
—
P/E (Fwd)
-5.87
EPS (TTM)
$-0.27
EPS (Fwd)
$-0.15
ROE
-50.3%
ROA
-29.3%
Cash
$2.1M
Total Debt
$482,562
Free CF
-$2.7M
52W Change
-53.7%
Annual Financials
Cash vs Debt
Where GDTC stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, GDTC finished 12.00% below its 150-day moving average ($1.00) and 21.43% below its 200-day moving average ($1.12). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GDTC overbought or oversold?
At the September 3, 2026 close, GDTC's RSI(14) was 52.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $2.1M in cash comfortably exceeding the $483K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$2.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -50.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, CytoMed Therapeutics Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, GDTC has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GDTC.